Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination

Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination

“…This fact and our previous result [7] suggest that DC vaccination may have the possibility to induce tolerance of tumor as well as antigen-specific anti-tumor immunity.…”

“…While we have also shown histopathologically that DC vaccination causes loss of MHC class I expression and downregulation of tumor antigens in metastases [3], and an increase of Treg as well as DC, CD4 + , CD8 + , and IFN-g + cells in DTH site [7]. Furthermore, we found no statistically significant increase in survival in patients treated with DC vaccination compared with those receiving conventional therapy [8].…”

“…All were patients that participated in previous study [3]: patient 1, 2, 3, 4, 5, 6, 7, 8, and 9 were corresponded with patient 5, 3, 7, 4, 6, 16, 8, 2, and 13, respectively. Six of 9 were also patients that participated in previous study [7]: patient 1, 2, 3, 5, 6, and 8 were corresponded with patient 3, 2, 5, 4, 7, and 1, respectively. Entry criteria included age over 18 years old, expression of HLA-A2 or HLA-A24 on PBMCs, and anticipated survival of greater than 3 months.…”

“…Delayed type hypersensitivity was examined as described previously [3,7]. Briefly, patients received intradermal injections of 200 ml of PBS with 10 mg of MAGE-1, 2, 3, tyrosinase and MART-1 respectively, or 20 mg of tumor lysate at separate sites on the forearm.…”

Twelve-year survival and immune correlates in dendritic cell–vaccinated melanoma patients

“…Indeed, in such DC vaccine reaction sites beside antigen-specific T cells (96,97), an infiltration with eosinophils was also found (98), meaning that the vaccine injection site reactions should constitute an ideal and accessible model to study the role of eosinophils in T cell migration and mechanistic issues also in man. A trend for the correlation between local vaccine reactions and clinical benefit has been reported in various DC vaccine trials previously, but results were inconsistent (99, 100).…”